Details of the Drug Reposition

General Information of This Drug (ID: DMCOZJY)

Drug Name
Tenapanor   DMCOZJY
Synonyms
1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Irritable bowel syndrome DIS27206 DD91.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Kidney disease DISK7GAB GC2Z Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health.